New drug combo tested for rare, aggressive cancer
NCT ID NCT07328425
Summary
This study is testing whether a combination of two chemotherapy drugs, lurbinectedin and irinotecan, can help control advanced desmoplastic small round cell tumor (DSRCT), a rare and aggressive cancer. It is for patients aged 15 and older whose cancer has spread and worsened after initial standard chemotherapy. The main goal is to see if the treatment shrinks tumors and for how long it keeps the cancer from growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DESMOPLASTIC SMALL ROUND CELL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione IRCCS Istituto Nazionale dei Tumori
RECRUITINGMilan, MI, 20133, Italy
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.